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Abstract  
Mutations in the collagen genes COL4A1 and COL4A2 cause Mendelian eye, kidney and 
cerebrovascular disease including intracerebral haemorrhage, and common collagen IV 
variants are a risk factor for sporadic intracerebral haemorrhage. COL4A1 and COL4A2 
mutations cause endoplasmic reticulum (ER) stress and basement membrane (BM) defects, 
and recent data suggest an association of ER stress with intracerebral haemorrhage due to a 
COL4A2 mutation. However, the potential of ER-stress as a therapeutic target for the multi-
systemic COL4A1 pathologies remains unclear. We performed a preventative oral treatment 
of Col4a1 mutant mice with the chemical chaperone phenyl butyric acid (PBA), which 
reduced adult intracerebral haemorrhage. Importantly, treatment of adult mice with 
established disease also reduced intracerebral haemorrhage. However, PBA treatment did 
not alter eye and kidney defects, establishing tissue specific outcomes of targeting Col4a1-
derived ER stress, and therefore this treatment may not be applicable for patients with eye 
and renal disease. While PBA treatment reduced ER-stress and increased collagen IV 
incorporation into BMs, the persistence of defects in BM structure and reduced ability of 
the BM to withstand mechanical stress indicate PBA may be counter-indicative for 
pathologies caused by matrix defects. These data establish that treatment for COL4A1 
disease requires a multi-pronged treatment approach that restores both ER homeostasis 
and matrix defects. Alleviating ER-stress is a valid therapeutic target for preventing and 
treating established adult intracerebral haemorrhage, but collagen IV patients will require 
stratification based on their clinical presentation and mechanism of their mutations.  
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Introduction 
Diseases caused by mutations in extracellular matrix components are traditionally 
considered matrix diseases but many mutations elicit intracellular consequences (1). This 
has generated increasing interest in delineating the role of these intracellular responses in 
pathology and their potential as a therapeutic target. The basement membrane (BM) is an 
extracellular matrix structure that provides structural support, compartmentalises tissues 
and influences cell behaviour and signalling (2). Collagen IV is a major BM component and in 
vertebrates the genes COL4A1-COL4A6 encode six collagen IV alpha chains [α1(IV)- α6(IV)]. 
These alpha chains assemble into three networks, α1α1α2(IV), α3α4α5(IV), α5α5α6(IV), of 
which is α1α1α2(IV) is the most widely expressed (3). COL4A1/COL4A2 mutations cause a 
multi-systemic disorder encompassing cerebrovascular disease, including intracerebral 
haemorrhage (ICH), as well as eye and renal defects (4-7) including HANAC syndrome (8, 9). 
The variability in clinical presentation and severity means not every patient develops eye or 
kidney pathology in addition to cerebrovascular disease (7, 10). The identification of rare 
mutations in sporadic haemorrhaging (11, 12), and that common COL4A2 variants are a risk 
factor for deep ICH (13) and white matter hyperintensities (14) in the general population, 
underscore an important role for COL4A1/COL4A2 in common cerebrovascular disease and 
ICH. ICH accounts for 15% of adult stroke and 50% of paediatric stroke (15), and besides 
generic risk reducing approaches, there are no specific treatments.  
Mouse models with Col4a1 missense mutations such as Col4a1+/SVC are excellent tools to 
investigate therapeutic strategies. They display ICH (4, 16, 17), eye disease including 
anterior segment dysgenesis (18-20) and renal disease including Bowman’s capsule defects 
and tubular dysfunction (18, 21, 22). Col4a1+/SVC mice harbours a glycine to aspartic acid 
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mutation affecting a highly conserved glycine residue of the Gly-X-Y repeat in the collagen 
domain of α1(IV) (18, 22), equivalent to the vast majority (>85%) of COL4A1/COL4A2 
mutations.  
There are no treatments for diseases caused by COL4A1/COL4A2 mutations, and the disease 
mechanisms remain poorly understood. Endoplasmic reticulum (ER) stress has emerged as a 
potential disease mechanism in addition to matrix defects for mutations in matrix 
components including collagen (1). Besides ECM defects, collagen IV mutations can lead to 
intracellular accumulation of collagen IV and ER stress (17, 18, 23, 24). Genetic evidence 
from a family with a COL4A2 mutation indicated that ER retention of α1α1α2(IV) and 
subsequent ER-stress is associated with porencephaly and ICH (25), which was supported by 
animal data (26). ER stress due to ER retention of secreted protein elicits the unfolded 
protein response (UPR) that entails three signalling arms: cleavage of XBP1 by IRE-1, 
proteolytic cleavage of ATF6, and phosphorylation of eIf2α causing upregulation of ATF4 
(27). ER stress has been observed in a wide spectrum of diseases such as (cerebro)vascular, 
renal(28-30) and ocular(31), pathologies, including age related disease(32), but for many of 
these disorders, including adult ICH, its potential as therapeutic target remain unclear. 
Interestingly, ER stress can be targeted using compounds including 4-sodium phenyl 
butyrate (PBA), a FDA-approved chemical chaperone (33).  
Here, we set out to determine the efficacy of PBA as a treatment for adult COL4A1/4A2 
pathologies. Our data establish that reducing ER stress is a therapeutic avenue for 
preventing and treating established adult ICH, but is not for effective eye and renal 
pathologies and can be counter-indicative for pathologies due to BM defects as it reduces 
their ability to withstand mechanical stress. This highlights the need for patient stratification 
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for such treatment approaches based on both their clinical presentation and knowledge of 
the underlying mechanism of their specific mutations. 
 
Results 
Targeting ER stress as a preventative treatment for intracerebral haemorrhage 
As defects due to COL4A1 mutations can present in childhood, a therapeutic approach will 
likely be long term and would preferentially be orally administered. To model this 
preventative treatment, we treated Col4a1+/SVC mice (18, 34) orally with PBA from 
conception, by treatment of pregnant dams, and ICH was determined in 5-month old adult 
mice, treated daily (Fig. 1A). Magnetic resonance imaging (MRI) of the mid brain revealed 
that most ICH is centred towards the basal ganglia and, importantly, a ~50% reduction in 
bleed volume of PBA treated Col4a1+/SVC mice (Fig. 1B & 1C). As PBA did not affect the 
number of haemorrhages, this reduced severity is obtained by modulating bleed volume 
(Fig. 1C). Histopathological analysis using Prussian Blue stain for hemosiderin (Perl’s 
staining) confirmed the MRI data (Fig. 1D & 1E). Col4a1+/SVC display increased levels of Iba1, 
a marker for neuroglial activation that is the initial step in the CNS inflammatory response 
following stroke (35), which was reduced in treated mice (Fig. 1F & 1G), supporting reduced 
cerebrovascular disease severity and neuroinflammation. Tail cuff plethysmography 
revealed no significant change in systolic blood pressure in mutant mice (Supplemental 
Figure 1), indicating the reduction in ICH is not dependent on altered vascular haemostasis. 
Modification of eye and renal defects. 
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Col4a1 renal disease encompasses glomerular defects including hypertrophy of Bowman’s 
capsule and glomerulocystic kidney disease (18, 21, 22), as well as tubular defects that are 
associated with polyuria (increased urine production) (22). Preventative PBA treatment 
reduced polyuria (Fig. 2A). However, both untreated and treated mice displayed defects of 
the parietal epithelium in Bowman’s capsule with a cuboidal appearance of epithelial cells, 
suggestive of epithelial cell activation (21) (Fig. 2B), and/or formation of multiple cell layers 
(18, 21, 22): ~74% (75/102) and ~73% (70/96) of Bowman’s capsules of untreated and 
treated mice, respectively (Fig. 2B-C & 2E). Col4a1 glomerulocystic kidney disease includes 
retraction of the capillary tuft (21), which was detected in ~18% (19/103) of glomeruli in 
untreated mice and ~15% (14/94) of treated mice (Fig. 2B, 2D & 2F). The occurrence of 
capillary tuft retraction in Col4a1+/SVC appears to occur in glomeruli that do not appear to 
exhibit the parietal epithelial cell defect (Fig. 2B). Evidence of atrophy of the medulla also 
remained (Supplemental Figure 2B). These data indicate a differential response whereby 
Bowman’s capsule and glomerular defects are recalcitrant to PBA treatment while polyuria 
appears reduced. 
In the eye, Col4a1 mutations can lead to anterior segment dysgenesis (ASD) encompassing 
corneal clouding, cataracts, iris hypoplasia and buphthalmos (enlargement of the anterior 
chamber) on slit lamp examination (Fig 2I) (5, 18, 20). PBA treated and untreated mice 
showed iris-corneal adhesions, dysgenic ciliary body, and reduced or absence of trabecular 
meshwork (Fig. 2G & 2H). Severity scoring revealed PBA treatment did not alter ASD severity 
(Fig. 2H), while slit lamp analysis revealed iris hypoplasia, corneal clouding and 
neovascularisation in treated and untreated mice (Fig. 2I and 2J). The inner and outer retinal 
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nuclear layers in Col4a1+/SVC can appear disorganised (Supplemental Figure 3B) and optic 
nerve cupping remains present following PBA treatment (Supplemental Figure 3D).  
Investigating the efficacy of PBA treatment on established phenotypes.  
Treatment from conception or birth provides a proof-of-principle preventative approach 
that would only be possible for some familial cases. In most cases treatment will occur post 
ICH and molecular diagnosis. We therefore treated 4 month old Col4a1+/SVC for 1-month to 
determine if PBA can reduce established disease (Fig. 3A). While ICH severity was 
maintained on MRI analysis (Fig 3B & 3C), ICH was significantly reduced based on 
histopathology using Perl’s stain (Fig. 3D & 3E). It should be taken into account that the 
resolution of our MRI analysis is not sufficient to detect microbleeds. Therefore, our data 
establishes that PBA can reduce established adult cerebrovascular phenotypes and suggests 
that PBA mainly affects small microbleeds not detectable with MRI. 
Slit lamp analysis and histopathology did not reveal amelioration of ASD following treatment 
(Fig. 3F & 3G). Histopathological analysis of the retina did show a trend towards reduced 
optic nerve “cupping”, which in Col4a1 mutant mice reflect optic nerve hypoplasia (23), but 
signs of retinopathy were also observed (Supplemental Figure 3C-D). In the kidney, defects 
in the parietal epithelium of Bowman’s capsule occurred in ~74% (86/116) Bowman’s 
Capsules (Fig. 3H), and cystic changes in ~5% (6/116) glomeruli (Fig. 3I), compared to 74% 
and 18% in untreated mice, while polyuria (Supplemental Figure. 2) was also observed. 
Thus, in our hands PBA has very limited efficacy for eye and glomerular renal phenotypes 
both as a preventative measure and treatment approach.  
PBA reduces ER stress and increases deposition of collagen IV in the basement membrane. 
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To determine if PBA was able to reduce ER stress levels in vivo, we assessed protein levels of 
ER stress markers Bip and Atf4 in kidney of adult Col4a1+/SVC mice treated from conception, 
which revealed a significant reduction in their levels (Fig. 4A-B). Reduced ER stress was also 
observed in mice treated for 1 month (Supplementary Figure 4). To further illuminate the 
mechanism of PBA we performed immunostaining against Col4a1 on kidney sections as 
kidney contains vascular, epithelial and glomerular BMs. Both lifelong and 1-month PBA 
treatment increased staining of Col4a1 within the BMs (Fig. 4C-D), indicating that the 
reduced ER stress is coupled with increased secretion and staining of collagen IV in the BM. 
The absence of increased staining of collagen IV in lifelong versus 1-month treatments also 
suggests that long term chemical chaperone treatment may not have additional long-term 
improvement/restoration of collagen IV deposition within the BM compared to a shorter 
treatment. Besides being a chemical chaperone PBA can also inhibit histone de-acetylation 
activity, which could lead to increased transcription of collagen IV. QRT-PCR analysis on 
mRNA samples from kidneys from untreated and lifelong treated mice revealed PBA did not 
alter collagen IV mRNA levels (Supplemental Figure 5), supporting that the increased 
collagen IV staining is due to the chemical chaperone activity of PBA. 
Effects of chemical chaperone on BM structure function 
To determine if increased collagen IV deposition alters BM structure we performed 
transmission electron microscopy (EM) analysis of kidney, which enables analysis of 
vascular, endothelial and epithelial BMs. In wild type mice PBA did not alter collagen IV 
deposition (Supplemental Figure 6). In mutant mice, despite increased collagen IV staining 
(Fig. 4E), PBA did not affect mean thickness of renal and vascular BMs (Supplemental Figure 
7A-D) but BMs were characterised by a large variation in thickness (Supplemental Figure 7C-
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D). EM analysis revealed PBA treatment did not affect tubular BM structure (Fig. 5A), which 
is unaffected in Col4a1+/SVC mice (Fig. 5A and (22)). However, we did occasionally observe 
small focal duplications in some animals (1-month treatment: 1/4 animals; lifelong 
treatment; 2/5 animals) (Supplemental Figure 7E). Defects in BM of Bowman’s capsule 
included an irregular appearance, lamellation and multiple layers, as observed for untreated 
Col4a1 mutant mice (Fig. 5B and (18, 22)). Although overall reduction of ER stress levels was 
observed, some treated animals displayed more prominent ER vesicles in parietal epithelial 
cells of Bowman’s capsule (Fig. 5B). The GBM of treated and untreated animals were similar 
with irregular GBM thickness (Fig. 5C and (22)) but average thickness remained unchanged 
(Supplemental Figure 7C). However, PBA treatment appears to result in a reduction in the 
variability of GBM thickness (Supplemental Figure 7C). The vascular BM revealed 
heterogeneity whereby the BM in treated animals appeared in some sections more 
continuous compared to untreated mice (Fig. 5D). However, significant areas of apparent 
BM absence, disruptions, and diffuse BMs with reduced electron density were also 
observed. Both treated and untreated Col4a1+/SVC mice showed fibrillar collagen deposition 
(Fig. 5D). Taken together these data indicate PBA treatment does not significantly improve 
BM ultrastructure.  
Given the increased deposition of collagen IV into the BM, we investigated if this affected 
BM strength. The dermal BM is critical for adhesion of the epidermis to the dermis, and 
dermal BM defects cause blister formation in epidermolysis bullosa (36). Tape stripping on 
the back skin of mice generates mild mechanical stress, which enables a measurement of 
the ability of the BM to withstand separation of the dermis from the epidermis and blister 
formation (37). We employed this tape stripping procedure followed by PAS staining (Fig 6A) 
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to assess the ability of the BM to withstand mechanical stress as a measure of its strength. 
Compared to WT, Col4a1+/SVC showed increased separation of dermis from the epidermis, 
indicating a weaker BM (Supplemental Figure 8). Surprisingly, PBA did not reduce the level 
of separation but apparent increased severity was observed (Fig. 6B). These results provide 
evidence that increased collagen IV secretion in mutant mice and chemical chaperones can 
reduce the ability of BMs to withstand mechanical strength.  
Discussion 
Disorders due to mutations in BM and matrix components are rare diseases and for most of 
these diseases treatment remains a long-term goal. Specific treatments are often also 
lacking for common diseases including haemorrhagic stroke that accounts for 15% of adult 
stroke and is a major burden on society (15). Developing specific or more effective 
treatments is underpinned by understanding disease mechanisms. Mutations in 
COL4A1/COL4A2 cause ER stress and BM defects (10, 22, 25) and while ER stress occurs in a 
large number of diseases, including extracellular matrix disorders (1, 38), the efficacy of 
targeting ER stress as a long-term therapeutic approach for adult onset diseases, either as 
preventative approach or as treatment of existing conditions, is an important question to 
address. Mutations in ECM and BM components most often result in complex multi-
systemic diseases (36). Therefore, it is important to adopt a holistic approach and determine 
the efficacy of compounds across a spectrum of affected tissues. 
We performed a chemical chaperone treatment to target ER stress in mice carrying a Col4a1 
glycine missense mutation, the most common mutation type identified in patients (39). 
While ICH due to COL4A1/COL4A2 mutations can occur throughout life (4, 6, 17, 19, 36, 40), 
many of the vascular and extra-vascular pathologies, including renal and eye defects, 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy369/5142417 by guest on 19 N
ovem
ber 2018
11 
 
develop with age and present in adulthood in mice (18, 22, 41). We therefore performed a 
PBA treatment from conception to investigate if targeting ER stress can prevent adult 
disease. We focused on ICH as it underlies the cerebrovascular pathologies caused by 
COL4A1/COL4A2 mutations, including porencephaly and small vessel disease (10). This 
revealed that an oral preventative PBA treatment reduces adult ICH due to Col4a1 glycine 
mutations. These data are supported by a short term PBA treatment of newborn pups (26) 
and mice harbouring a very severe splice mutation (42). However, preventative treatment 
from birth or early childhood will likely only be possible for rare familial cases following 
molecular diagnosis/prenatal screening. For the majority of cases treatment will and can 
only commence after ICH and molecular diagnosis has occurred, which also applies to 
sporadic ICH in the general population for which collagen IV is a risk factor (11-14). 
Interestingly and importantly, treating adult mice for 1 month with PBA reduced total ICH, 
providing strong evidence that targeting ER stress using chemical chaperones has efficacy as 
a treatment for pre-existing ICH and COL4A1 associated cerebrovascular disease.  
A core requirement of personalised medicine is to delineate patient groups for which a 
particular treatment is recommended and those for which alternative approaches are 
required. Investigating the mode of action of treatments in light of the pathomolecular 
disease mechanisms is therefore important. Besides a chemical chaperone PBA can also act 
as a histone deacetylase inhibitor (43). The absence of altered collagen IV mRNA levels 
provides evidence that PBA is acting through its chemical chaperone activity. In addition, 
although PBA has been shown to be able to reduce blood pressure in hypertension (44), it 
did not affect blood pressure in our model, indicating its effects on ICH is independent of 
blood pressure. PBA treatment reduced ER stress and increased deposition of collagen IV in 
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BMs, which was associated with reduced mechanical strength of the BM.  This increased 
secretion in response to PBA treatment in vivo is supported by data from other matrix 
diseases including Pierson syndrome due to laminin B2 mutations(29), and Osteogenesis 
Imperfecta caused by a Col1a1 mutation (45). As our model is heterozygous for the causal 
mutation (18), similar to human patients (39), we were not able to determine if the secreted 
collagen is mutant or wild-type collagen. Similarly, the extent to which this additional 
secreted collagen IV is integrated into the BM remains to be determined. However, our data 
do indicate that promoting collagen secretion via chemical chaperone treatment is counter-
indicative for COL4A1 pathologies caused by BM defects as PBA treatment reduced the 
ability of BM to withstand mechanical stress. In addition, the persistence of eye and renal 
defects indicate chemical chaperone treatment represents a potential therapeutic approach 
for patients that present only with COL4A1-associated ICH but is not effective for those that 
also exhibit renal or eye disease, establishing a criterion for patient stratification. The 
apparent lack of effectivity for the eye phenotype may be related to the avascular nature of 
the adult lens, which plays a key role in Col4a1 eye disease (46), as previous data in cartilage 
(47) suggested PBA is not effective for avascular tissues. It will now also be important to 
establish if the lack of effectivity for Col4a1 renal disease also applies to other kidney 
pathologies due to mutations in BM components such as Alport syndrome, where PBA 
reduced ER stress in cells with COL4A5 missense mutations (48).  
The tissue specific outcomes of our treatment also illustrate the urgent need to increase our 
understanding of the molecular disease mechanisms. Our previous work in kidney showed 
that Col4a1 Bowman’s capsule defects were associated with matrix defects, and the tubular 
disease with ER stress as it occurred in the absence of BM defects and was associated with 
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chronic ER stress levels (22). The involvement of ER stress in the eye disease has remained 
unclear with apparent conflicting data (46, 49). Given the reduced ER stress and ICH 
following treatment, and persistence of matrix defects and kidney pathology, these data 
provide significant evidence to the hypothesis that collagen IV mutations may elicit cell 
and/or tissue specific responses and disease mechanisms, with varying contributions of ER 
stress and/or matrix defects. In this case, it is tempting to suggest a major role of matrix 
defect in the Bowman’s capsule pathology, and ER stress in cerebrovascular disease. 
However, while many COL4A1/COL4A2 mutation in mice and patients cause matrix defects 
and intracellular retention (7, 18, 25), not all mutations elicit the same cellular response 
(24). For example mice homozygous for the Col4a1 G498V mutation, detected in HANAC 
patients, are viable (21) in contrast to other glycine mutations in mice (4, 18, 19), while 
other non-glycine mutations do not appear to cause ER-stress (24) and presumably act 
though matrix defects. Given that our data lead us to suggest that chemical chaperone 
treatment may not be warranted for COL4A1/4A2 mutations that act via matrix defects and 
do not cause ER stress, it is important to delineate the actual contribution of intra- and 
extracellular sequelae to disease pathogenesis and confirm treatment efficacy across 
different Col4a1/Col4a2 mutations.  
In conclusion, our data establish that reducing ER stress is a therapeutic avenue for 
preventing and treating established adult intracerebral haemorrhage but can be counter-
indicative for pathologies due to extracellular matrix defects as it reduces their ability to 
withstand mechanical stress.  This highlights the need for patient stratification for such 
treatment approaches based on both their clinical presentation and knowledge of the 
underlying mechanism of their specific mutations.  
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Materials and Methods 
Animal studies were performed in accordance with UK Home Office regulations (Project 
license 70/8604). PBA (1g/kg/day) (33) was administered orally via drinking water (lifelong 
treatment), or via gavage (1 month treatment). Animals were randomly allocated to 
treatment/no-treatment group before genotyping and development of overt phenotypes. 
Samples were labelled numerically and did not display treatment/genotype status, blinding 
the researcher. Un-blinding occurred following completion of datasets. 
Metabolic cage studies. Animals were individually housed and allowed to acclimatise (24 
hours). Daily urine samples were collected and water consumption measured.  
Tail plethysmography was performed as previously described (17). 
Slit lamp analysis was performed as described (18). 
MRI Analysis.  MRI scanning was performed on a 7Tesla Bruker Biospec scanner (Bruker). A 
72cm volume resonator birdcage coil was used for transmitting and 4-channel phased array 
surface coil for receiving the MRI signal. A gradient echo imaging sequence was used to 
acquire T1 weighted images, with the following parameters: 1.76cm x 1.76 cm Field of View, 
176 x176 matrix, 100μm x 100μm, 14 coronal slices, thickness 0.5mm, repetition time 
200ms, echo time 3.3ms, 8 averages, flip angle 30°, total scan time 4min 41sec. The 14 slices 
were acquired back from the rhinal fissure, excluding the olfactory bulb and cerebellum. 
Images were acquired and reconstructed using Bruker Paravision 5.1 software.  Images were 
analyzed using ImageJ software to calculate bleed volumes and number of bleeds. 
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Dermal BM analysis was performed by repeated application and removal of autoclave tape 
on shaven dorsal skin. Following dissection of skin areas, samples were processed for 
histology. ImageJ was used to measure ratio of basement separation versus length of 
epidermis, excluding hair follicles. 
Histopathology. Tissues were fixed (10% neutral buffered formalin or 4% 
paraformaldehyde) and paraffin embedded. Sections were stained with Haematoxylin-Eosin 
or Perl’s Prussian Blue using standard protocols. For Perl’s Prussian Blue staining to assess 
ICH, Image analysis was performed using ImageJ, colour threshold plugin (50) to calculate 
the area of the section stained positive for hemosiderin. A ratio of the bleed area versus 
tissue section area represent bleed percentage. For each brain, 6 sections of the midbrain, 
separated by 250 µm, were analysed and the total area of the section stained positive for 
hemosiderin was determined. Skin sections were stained with PAS using standard protocols. 
Histopathology of eye and kidney section was performed using Haematoxylin-Eosin staining. 
Eye section were scored based on (20). Briefly, scoring of anterior segment defects was 
based on presence/absence of iridocorneal adhesion, ciliary body morphology with 3-5 
foliation being considered normal, presence/absence of open Shlemms canal). Absence of 
iridocorneal adhesion, 3-5 foliation of the ciliary body and presence of open Shlemms canal 
was given a score of 1 whereas defects were scored as 0. Mean anterior segment dysgenesis 
score was calculated per animal with a maximum score of 6. Kidney sections were scored for 
the presence of defects in Bowmans capsule (including cuboidal appearance of parietal 
epithelial cells, formation of multiple cell layers) and glomerulocystic kidney disease 
(retraction of the glomerular tuft, dilation of Bowman’s Space, circumference of Bowman’s 
capsule measured using the segmented line tool in Image J) as described(21). Statistical 
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analysis was performed on glomerulus/Bowman’s Capsule data from >10 random images of 
3 sections per animal of 4 mice.  
Electron microscopy analysis. Tissues were fixed in 2% glutaraldehyde in phosphate buffer 
and processed as described (34). EM thickness was measured as described (22): 
Measurements were taken every ~800 nm in at least 3 animals with 3-5 structures (e.g. 
Bowman’s capsule) analysed per animal. Statistical analysis was performed using averages 
of individual structures. 
QRT-PCR analysis was performed as previously described (17). mRNA extracts were 
prepared using Tri-reagent followed by cDNA synthesis using Affinity Script cDNA Synthesis 
Kit as per manufacturer instructions. RT-PCR was performed in triplicate using Power SYBR 
Green PCR Master Mix (Fisher Scientific) as per manufacturer instructions. Analysis of mRNA 
levels was performed using the ΔCT method and was corrected for 18S ribosomal RNA. 
Immunoblotting. Protein extracts were prepared in RIPA buffer containing protease (Roche 
Applied Science) and phosphatase inhibitors (Phostop Roche). Membranes were blocked 
with 5% milk or BSA before incubation with primary antibodies (BIP (1/10,000, BD 
Transduction), ATF4 (1/2500 Santa Cruz)), HRP-conjugated secondary antibodies (GE 
healthcare) and development using chemiluminescense (Millipore). Protein levels were 
corrected for Coomassie staining of total protein gels ran or protein stain on membrane 
(Memcode, Pierce). Densitometry was performed using Image J.  
Immunohistochemistry. Staining against collagen IV (H22 for Col4a2; 1/100) on cryosections 
was performed as described (22, 34). Paraffin embedded sections underwent antigen 
retrieval using citrate buffer, were incubated with primary antibodies against IBA1, then 
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counterstained using Impress DAB kit (Vector laboratories). Images were captured using a 
Axiocam microscope and Zen (Zeiss) imaging software.  
Statistical analysis (Graphpad Prism) was done by unpaired Student’s t-test, Chi Square or 
One way Anova with post hoc analysis.  
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Figure Legends 
Figure 1. PBA reduces intracerebral haemorrhage. (A) Overview of preventative PBA 
treatment from conception to point of analysis. (B) MRI image of untreated and treated SVC 
mice showing ICH (red arrow). (C) Image analysis of MRI data reveals reduced ICH bleed 
volume (left graph) but not ICH number of bleeds (right graph) (WT n = 6, SVC n =10, SVC 
PBA n = 6)). (D) Perls staining of brains from 5 month old untreated Col4a1+/SVC and 
Col4a1+/SVC treated from conception (blue staining). (E) Image analysis of Perls staining ICH 
(WT n= 7, SVC n=6, SVC PBA n=12). (F) Immunostaining against Iba1 (brown) on brain 
sections with detail of dashed square provided in small square. (G) Image J analysis of 
staining is provided in graph (WT n= 6, SVC n= 5, SVC PBA n = 3). One way Anova with post 
hoc test (Bonferroni (G), Tukey (E) ; *  p-value < 0.05; *** p-value <0.001) 
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Figure 2. Effect of PBA treatment on adult eye and renal defects. (A) Daily urine output of 5 
month old untreated wild type littermate (WT), untreated Col4a1+/SVC mice and treated 
Col4a1+/SVC (WT n= 20, SVC n = 18, SVC PBA n = 6). (B) Haematoxylin and eosin staining of 
kidneys revealed in untreated Col4a1+/SVC (SVC) and PBA treated Col4a1+/SVC mice (SVC PBA) 
defects (cuboidal appearance, formation of multiple cell layers) of parietal epithelial cells of 
Bowman’s capsule (black arrow) and glomerulocystic kidney disease (retraction of vascular 
tuft, green arrow). SVC: untreated Col4a1+/SVC. (n = 4). (C) Image analysis of Bowman’s 
capsules in WT (n = 75 capsules) and Col4a1+/SVC (n = 102) (χ2 = 42.52; 1 df). (D) Image 
analysis of glomerulocystic kidney disease in WT (n = 75 glomeruli) and Col4a1+/SVC (n = 102) 
(χ2 = 15.49; 1 df). (E) Image analysis reveals similar frequency of Bowman’s capsule defects 
in treated (n = 84) and untreated (n = 102) Col4a1+/SVC. (χ2 = 0.009; 1 df) (F) Image analysis 
reveals similar frequency of cystic defects in treated (n = 103 glomeruli) and untreated (n = 
94) Col4a1+/SVC (χ2 = 0.44; 1 df). (G) Haematoxylin and eosin staining of eyes revealed 
persistence of anterior segment dysgenesis defects in treated mice (SVC PBA) including 
iridocorneal adhesion (arrow), atrophy of the ciliary body (*) Size bar = 50µm. (H) Scoring of 
anterior segment (presence/absence of iridocorneal adhesion, ciliary body morphology, 
presence/absence of open Shlemms canal) in wild type (WT), untreated (SVC) and treated 
mutant (SVC + PBA) mice. (WT n = 4, SVC n=4, SVC PBA n = 6 mice)) (I) Slit lamp analysis 
revealed persistence of opacity of cornea (scoring system applies only to corneal opacity) 
and iris hypoplasia in treated mice. Corneal neovascularisation (see “severe” panel) is also 
observed. Right panel is graphical representation of scoring of corneal opacity. (SVC n=6, 
SVC PBA n = 4 animals). (J) Image analysis of corneal opacity scoring. C-F: Two-sided Chi-
square test; A, H: One way Anova post hoc Sidak Test* p-value<0.05, **** p-value <0.0001 
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Figure 3. PBA treatment of established disease. (A) Diagram of 1 month oral PBA treatment 
for treatment of established phenotypes in 5 month old mice. (B) MRI image of a mutant 
animal pre and post treatment reveals ICH (black arrow). (C) ImageJ analysis of MRI data 
based on bleed number (top) and bleed volume (bottom) (SVC n = 11, SVC PBA n = 8). (D) 
Perl’s staining of brains sections reveals ICH (blue staining) untreated and treated mutant 
mice (SVC and SVC 1M PBA). (E) Image analysis indicating percentage of tissue that stained 
positive for ICH (n=3). (F) Slit lamp analysis reveals persistence of corneal opacity and iris 
hypoplasia. Images are of same eye of animal pre and post treatment (n = 4 animals). (G) 
Scoring of anterior segment (presence/absence of iridocorneal adhesion, ciliary body 
morphology, presence/absence of open Shlemms canal) in untreated (SVC) and treated 
Col4a1+/SVC (SVC 1M PBA). (SVC n=4, SVC 1M PBA n = 4 mice) (H) Image analysis of 
Bowman’s capsule defects in untreated and treated mice (n=116) (I) Image analysis of 
glomerulocystic defects (χ2 = 9.506; 1 df, p=0.002). (Histopathology of eye and kidney is 
provided in Supplemental Figure 2 and 3).  D,E: One way Anova with Bonferonni post hoc 
test; F Two sided chi square * p-value < 0.05, *** p-value < 0.001 
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Figure 4. Chemical chaperone activity increases deposition of collagen IV in vivo (A) 
Western blotting showed increased levels of Bip (∼2.9-fold increase) and ATF4 (∼4.6-fold 
increase) in untreated Col4a1+/Svc (SVC unt) which is reduced following PBA treatment. 
Representative band of total protein stain is given as loading control (entire gel is provided 
in Supplemental Figure 9). (B) ImageJ densitometry analysis of Bip and ATF4 (n=3). (C) 
Immunostaining against Col4a1 in PBA treated and untreated Col4a1+/Svc mice (WT: wild 
type; SVC: untreated; SVC 1M PBA: 1 month treatment; SVC LL PBA: chronic treatment from 
conception) on kidney sections revealed increased deposition of Col4a1 following PBA 
treatment. (n=3-5 mice, Bowmans Capsule: SVC n = 30 , SVC 1M PBA n = 42,  SVC LLPBA n = 
16; Tubular BM SVC n = 89, SVC 1M PBA n = 77,  SVC LLPBA n = 47; Vascular BM SVC n = 36, 
SVC 1M PBA n = 23,  SVC LLPBA n =15). (D) ImageJ analysis of fluorescence staining. B, D One 
way Anova Post hoc Sidak test * p<0.05, ** p<0.01 *** p<0.001 
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Figure 5: Effect of PBA on BM structure. (A) Normal appearance of BM of tubules (white 
arrow) in untreated Col4a1+/SVC (SVC) and mice treated for 1 month at 4 months of age (SVC 
1M PBA) or from conception for 5 months (SVC LL PBA). (B) Severe defects in BM of 
Bowman’s capsule in all mice including bulges (white arrow SVC), basket weave appearance 
(white arrow SVC 1M PBA), multiple layers (white arrow SVC LL PBA). Evidence of enlarged 
ER (red arrow SVC 1M PBA) and increased vesicles (red arrow SVC LL PBA) is also observed. 
(C) Irregular thickening (white arrow) of glomerular BM (GBM) in treated and untreated 
mice. Thinner BM areas are also observed (black arrow) (D) Vascular BM (VBM) defects 
include interruption (white arrow SVC, 1M PBA), presence of collagen fibrils (white arrow 
bottom panel 1M PBA) and more fuzzy but continuous BM (bottom panel LL PBA) Black size 
bar 1 micron, white size bar 5 µm. One way Anova Post hoc Tukey test * p<0.05, ** p<0.01, 
*** p<0.001 
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Figure 6. PBA does not improve BM strength. (A) PAS stain of tissue section from 
Col4a1+/SVC and 1 month treated Col4a1+/SVC (SVC PBA) with shows separation of dermis 
from epidermis (circle). (B) Image J analysis revealed increased separation in treated mice 
(SVC n = 7, SVC PBA n = 4) Unpaired t-test * p<0.05 (Stain of wild type littermate is provided 
in supplemental Figure 8) 
 
 
Supplemental Figures 1-9 are provided in Supporting Information  
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